BlackRock Amends Denali Therapeutics Stake, Maintains Position
Ticker: DNLI · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech
TL;DR
**BlackRock still owns Denali stock, signaling continued institutional confidence.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 25, 2024, indicating its ownership of Denali Therapeutics Inc. common stock as of December 31, 2023. This amendment, the third for BlackRock, shows that the investment giant continues to hold a significant stake in Denali. For investors, this signals that a major institutional player maintains confidence in Denali Therapeutics, which could be seen as a positive indicator for the stock's stability and long-term prospects.
Why It Matters
This filing shows that BlackRock, a massive institutional investor, still holds a significant position in Denali Therapeutics, which can reassure current and potential investors about the stock's institutional backing.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative risks for the company.
Analyst Insight
A smart investor would view this as a routine update confirming institutional presence, but would still conduct their own due diligence on Denali Therapeutics' fundamentals and future prospects rather than solely relying on BlackRock's position.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Denali Therapeutics Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A
- 24823R105 (other) — the CUSIP number for Denali Therapeutics Inc. Common Stock
Forward-Looking Statements
- BlackRock will maintain a significant stake in Denali Therapeutics Inc. for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major institutional investment firm.
What company's securities are being reported on?
The securities being reported on belong to Denali Therapeutics Inc., specifically their Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023.
What is the CUSIP number for the securities mentioned?
The CUSIP number for Denali Therapeutics Inc. Common Stock is 24823R105.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Denali Therapeutics Inc. (DNLI).